Optimization of a parallel artificial membrane permeability assay for the fast and simultaneous prediction of human intestinal absorption and plasma protein binding of drug candidates: Application to dibenz[b,f]azepine-5-carboxamide derivatives

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 530-540

  Fortuna, Ana ^a,b   Alves, Gilberto ^b,c   Soares da silva, Patrício ^d   Falcão, Amílcar ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^d DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

Biopharmaceutics Classification System; Dibenz b; F azepine 5 carboxamide derivatives; High throughput technology; Intestinal absorption; Parallel artificial membrane permeability assay; Permeability; Protein binding; Transcellular transport; Volume of distribution

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; ACETYLSALICYLIC ACID; AMIDE; ATENOLOL; BIA 2 024; BIA 2 059; BIA 2 265; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CHLORAMPHENICOL; CHLOROTHIAZIDE; DIBENZ[B,F]AZEPINE 5 CARBOXAMIDE DERIVATIVE; ESLICARBAZEPINE ACETATE; HYDROCHLOROTHIAZIDE; IBUPROFEN; KETOPROFEN; LICARBAZEPINE; METOPROLOL; NADOLOL; NAPROXEN; NORFLOXACIN; OXCARBAZEPINE; PIROXICAM; PROPRANOLOL; RANITIDINE; SALAZOSULFAPYRIDINE; SULPIRIDE; THEOPHYLLINE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; ARTIFICIAL MEMBRANE; ASSAY; DISTRIBUTION VOLUME; DRUG ABSORPTION; HUMAN; INTESTINE ABSORPTION; LIPID MEMBRANE; MEMBRANE PERMEABILITY; PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY ASSAY; PH; PKA; PLASMA PROTEIN BINDING; ULTRAFILTRATION;

EID: 84455169538     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22796     Document Type: Article

References (29)

1. Waterbeemd H, Gifford E. 2003. ADMET in silico modeling: Towards prediction paradise? Nat Rev Drug Discov 2:192-204.
2. Wang J, Urban L. 2004. The impact of early ADME profiling on drug discovery and development strategy. Drug Discov World Fall 5:73-86.
3. Mondal SK, Mondal NB, Banerjee S, Mazumder UK. 2009. Determination of drug-like properties of a novel antileishmanial compound: In vitro absorption, distribution, metabolism, and excretion studies. Indian J Pharmacol 41:176-181.
4. Obata K, Sugano K, Machida M, Aso Y. 2004. Biopharmaceutics classification by high throughput solubility assay and PAMPA. Drug Dev Ind Pharm 30:181-185.
5. Fangerholm U. 2007. The role of permeability in drug ADME/PK, interactions and toxicity-Presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans. Pharm Res 25:625-638.
6. Li C, Nair L, Liu T, Li F, Pichardo J, Agrawal S, Chase R, Tong X, Uss AS, Bogen S, Njoroge FG, Morrison RA, Cheng K-C. 2008. Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochem Pharmacol 75:1186-1197.
7. Kansy M, Senner F, Gubernator K. 1998. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1:1007-1010.
8. Avdeef A, Tsinman O. 2006. PAMPA-A drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur J Pharm Sci 28:43-50.
9. Rajendran P, Jaggi M, Singh MK, Mukherjee R, Burman AC. 2008. Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Invest New Drugs 26:25-34.
10. Akamatsu M, Fujikawa M, Nakao K, Shimizu R. 2009. In silico prediction of human oral absorption based on QSAR analysis of PAMPA permeability. Chem Biodiv 6:1845-1866.
11. Dreassi E, Zizzari AT, Falchi F, Schenone S, Santucci A, Maga G, Botta M. 2009. Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data. Eur J Med Chem 44:3712-3717.
12. Ovadia O, Greenberg S, Chatterjee J, Laufer B, Opperer F, Kessler H, Gilon C, Hoffman A. 2011. The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol Pharm 8:479-487.
13. Singh SP, Wahajuddin Tewari, D, Pradhan T, Jain GK. 2011. PAMPA permeability, plasma protein binding, blood partition, pharmacokinetics and metabolism of formononetin, a methoxylated isoflavone. Food Chem Toxicol 49:1056-1062.
14. Gleeson MP. 2007. Plasma protein binding affinity and its relationship to molecular structure: An in silico analysis. J Med Chem 50:101-112.
15. Buttar D, Colclough N, Gerhardt S, MacFaul PA, Phillips SD, Plowright A, Whittamore P, Tam K, Maskos K, Steinbacher S, Steuber H. 2010. A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions. Bioorg Med Chem 18:7486-7496.
16. Perisic-Janjic N, Kaliszan R, Wiczling P, Milosevic N, Uscumlic G, Banjac N. 2011. Reversed-phase TLC and HPLC retention data in correlation studies with in silico molecular descriptors and druglikeness properties of newly synthesized anticonvulsant succinimide derivatives. Mol Pharm 8:555-563.
17. Obach RS, Lombardo F, Waters NJ. 2008. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385-1405.
18. Avdeef A. 2005. The rise of PAMPA. Expert Opin Drug Metab Toxicol 1:325-342.
19. Avdeef A. 2003. Permeability-Thin membrane model without retention. In Absorption and drug Development: Solubility, permeability and charge state; Avdeef A, Ed. Hoboken: John Wiley & Sons, Inc., pp 139-142.
20. Fortuna A, Alves G, Falcão A, Soares-da-Silva P. 2010. Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharm Drug Dispos 31:362-366.
21. Lobell M, Sivarajah V. 2003. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol Divers 7:69-87.
22. FDA. 2000. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on pharmaceutics classification system. US Department of Health and Human Services Food and Drug Administration. 1-23.
23. Seo PR, Teksin ZS, Kao JPY, Polli JE. 2006. Lipid composition effect on permeability across PAMPA. Eur J Pharm Sci 29:259-268.
24. Kansy M, Avdeed A, Fischer H. 2004. Advances in screening for membrane permeability: High-resolution PAMPA for medicinal chemists. Drug Discov Today Techn 1:349-355.
25. Ermondi G, Lorenti M, Caron G. 2004. Contribution of ionization and lipophilicity to drug binding to albumin: A preliminary step toward biodistribution prediction. J Med Chem 47:3949-3961.
26. Alves A, Figueiredo I, Falcão A, Castel-Branco M, Caramona M, Soares-da-Silva P. 2008. Stereoselective disposition of S- and R-licarbazepine in mice. Chirality 20:796-804.
27. Shaw SJ, Hartman AL. 2010. The controversy over generic antiepileptic drugs. J Pediatr Pharmacol Ther 15:81-93.
28. Vuignier K, Schappler J, Veuthey J-L, Carrupt P-A, Martel S. 2010. Drug-protein binding: A critical review of analytical tools. Anal Bioanal Chem 398:53-66.
29. Lázaro E, Lowe PJ, Briand X, Faller B. 2008. New approach to measure protein binding based on parallel artificial membrane assay and human serum albumin. J Med Chem 51:2009-2017.